Loading company…
Siranbio develops siRNA therapeutics for viral, metabolic, cardiovascular, autoimmune and central nervous system diseases.
Founded in 2022 and based in Suzhou, China, Siranbio develops small interfering RNA drugs, including candidates for hepatitis B and weight reduction. In August 2026, it raised Series A+ funding co-led by IDG Capital and Riverhead Capital, with participation from CS Capital, Huatai Zijin Investment, YuanBio Venture, Lanchi Ventures, Zhongqi Capital and Suzhou Haoping. The funding will support its dual-target and extrahepatic delivery pipelines.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in